mesoderm specific transcript pseudogene 2Genealiases: []
Q-omics provides the consensus-scored MESTP2 profile across patient tissues and cancer cell-line models. MESTP2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MESTP2 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MESTP2 RNA expression shows 6,081 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, BRCA, and STAD as cancer lineages where MESTP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MESTP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MESTP2 survival associations across molecular data types. MESTP2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MESTP2 RNA expression–survival associations across cancer types. High MESTP2 expression shows unfavorable associations in KICH, OV, LGG, BLCA, PAAD and KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MESTP2 RNA expression.
This table summarizes MESTP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MESTP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MESTP2 shows lower tumor expression in BRCA. The BRCA box plot shows higher MESTP2 RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p = .014).
This table shows molecular features associated with MESTP2 in patient tissues and cancer cell lines. In patient samples, MESTP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
